Patents by Inventor Ralph Henry

Ralph Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10280196
    Abstract: In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: May 7, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Suresh Kumar Thallapuranam, Srinivas Jayanthi, Jacqueline Morris, Alicia Brown, David McNabb, Ralph Henry
  • Patent number: 10220000
    Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 5, 2019
    Assignees: The Board of Trustees of the University of Arkansas, BioVentures, LLC
    Inventors: Daniel Fologea, Ralph Henry, Greg Salamo, Yuriy Mazur, Michael J. Borrelli
  • Publication number: 20180104188
    Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 19, 2018
    Applicant: The Board of Trustees of the University of Arkansas
    Inventors: Daniel Fologea, Ralph Henry, Greg Salamo, Yuriy Mazur, Michael J. Borrelli
  • Patent number: 9849087
    Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Daniel Fologea, Ralph Henry, Greg Salamo, Yuriy Mazur, Michael J. Borrelli
  • Patent number: 9676816
    Abstract: In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 13, 2017
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Suresh Kumar Thallapuranam, Srinivas Jayanthi, Jacqueline Morris, Alicia Brown, David McNabb, Ralph Henry
  • Publication number: 20170029461
    Abstract: In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine.
    Type: Application
    Filed: January 20, 2015
    Publication date: February 2, 2017
    Inventors: Suresh Kumar Thallapuranam, Srinivas Jayanthi, Jacqueline Morris, Alicia Brown, David McNabb, Ralph Henry
  • Publication number: 20160145597
    Abstract: In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 26, 2016
    Inventors: Suresh Kumar Thallapuranam, Srinivas Jayanthi, Jacqueline Morris, Alicia Brown, David McNabb, Ralph Henry
  • Patent number: 9023353
    Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 5, 2015
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Samuel Michael Owens, Ralph Henry, Alicia Brown
  • Publication number: 20140328905
    Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
    Type: Application
    Filed: November 8, 2012
    Publication date: November 6, 2014
    Inventors: Daniel Fologea, Ralph Henry, Greg Salamo, Yuriy Mazur, Michael J. Borrelli
  • Publication number: 20140271686
    Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 18, 2014
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Samuel Michael Owens, Ralph Henry, Alicia Brown
  • Patent number: 8808733
    Abstract: Disclosed are methods and compositions for the controlled release of a drug or agent from a liposome using light or radiation. Also disclosed are compositions comprising liposomes having a lipid layer, wherein the liposomes contain an agent, an enzyme capable of releasing the agent from the liposome, and an enzyme activator sequestered by a molecular cage. In another aspect, methods of delivering an agent to a target in a subject are disclosed.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 19, 2014
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Daniel Fologea, Greg Salamo, Ralph Henry, Michael J. Borrelli, Peter M. Corry
  • Publication number: 20120041357
    Abstract: Disclosed are methods and compositions for the controlled release of a drug or agent from a liposome using light or radiation. Also disclosed are compositions comprising liposomes having a lipid layer, wherein the liposomes contain an agent, an enzyme capable of releasing the agent from the liposome, and an enzyme activator sequestered by a molecular cage. In another aspect, methods of delivering an agent to a target in a subject are disclosed.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 16, 2012
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Daniel Fologea, Greg Salamo, Ralph Henry, Michael J. Borrelli, Peter M. Corry
  • Patent number: 7858756
    Abstract: The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (?) methamphetamine, (?) amphetamine, or (?) MDMA.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: December 28, 2010
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: S. Michael Owens, Melinda Gunnell, Yingni Chi, F. Ivy Carroll, Ralph Henry, Eric Peterson
  • Publication number: 20080125579
    Abstract: The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (?) methamphetamine, (?) amphetamine, or (?) MDMA.
    Type: Application
    Filed: June 15, 2007
    Publication date: May 29, 2008
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: S. Michael Owens, Melinda Gunnell, Yingni Chi, F. Ivy Carroll, Ralph Henry, Eric Peterson
  • Patent number: D633379
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: March 1, 2011
    Assignee: American Earth Anchors, Inc.
    Inventors: Paul A. Chambers, Ralph Henry